CureVac Logo mit Claim RGB.jpg
CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference
November 21, 2018 07:00 ET | CureVac AG
TÜBINGEN, Germany and BOSTON, Nov. 21, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan...
TBIO.jpg
Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights
November 08, 2018 16:21 ET | Translate Bio, Inc.
Continued progress with ongoing Phase 1/2 clinical trial in CF and towards IND submission for OTC Deficiency LEXINGTON, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a...
CureVac Logo mit Claim RGB.jpg
University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator
November 07, 2018 16:30 ET | CureVac AG
TÜBINGEN, Germany and BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, congratulates CureVac...
CureVac Logo mit Claim RGB.jpg
CureVac to Present Preliminary Phase I Data on CV8102, an Intratumoral RNA-based Cancer Therapy, at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
November 07, 2018 07:00 ET | CureVac AG
Data to be presented includes CV8102 as a single agent and in combination with anti-PD1 therapy TÜBINGEN, Germany and BOSTON, Nov. 07, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated...
CureVac Logo mit Claim RGB.jpg
CureVac präsentiert vorläufige Daten seiner Phase-I-Studie mit dem RNA-basierten Wirkstoff CV8102 zur intratumoralen Anwendung auf der 33. Jahrestagung der Society for Immunotherapy of Cancer
November 07, 2018 07:00 ET | CureVac AG
Die Daten umfassen CV8102 als Einzelwirkstoff und in Kombination mit einer Anti-PD1-Therapie TÜBINGEN, Deutschland / BOSTON, USA, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Das biopharmazeutische...
TBIO.jpg
Translate Bio to Participate in Upcoming Investor Conferences
November 01, 2018 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
CureVac Logo mit Claim RGB.jpg
CureVac verkündet den Start einer klinischen Phase-I-Studie mit mRNA-basiertem Tollwutimpfstoff
October 23, 2018 07:13 ET | CureVac AG
Studie soll erste Daten zur intramuskulären Anwendung des von CureVac neu entwickelten Impfstoffs am Menschen liefern TÜBINGEN, Deutschland / BOSTON, USA, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Das...
CureVac Logo mit Claim RGB.jpg
CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA Rabies Vaccine
October 23, 2018 07:00 ET | CureVac AG
Trial to provide first-in-human data for CureVac’s novel mRNA-based intramuscular rabies vaccine TÜBINGEN, Germany and BOSTON, Oct. 23, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated...
TBIO.jpg
Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference
October 18, 2018 07:30 ET | Translate Bio, Inc.
-- Findings support ongoing Phase 1/2 study of once-weekly nebulized MRT5005 in adults with cystic fibrosis -- LEXINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq:...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes
October 09, 2018 08:00 ET | Marina Biotech, Inc.
Research Triangle Park, NC, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...